Neurontin Ruling Would Kill Off-Label Use, 1st Circ. Hears
A pharmaceutical industry group on Tuesday backed Pfizer Inc.'s challenge of a $142 million jury award in multidistrict litigation over off-label marketing of painkiller Neurontin, telling the First Circuit that the...To view the full article, register now.
Already a subscriber? Click here to view full article